OLIPASS Corporation

A244460

KR7244460002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
519 ^KRW	-2.81%		0.00%	-32.95%

Mar. 18	OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	CI
Mar. 06	OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	CI

OLIPASS Corporation announced that it has received KRW 2.00002 billion in funding

August 09, 2017

On August 10, 2017, Olipass Co., Ltd. closed teh transaction.

Latest news about OLIPASS Corporation

OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	Mar. 17	CI
OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	Mar. 05	CI
OLIPASS Corporation announced that it expects to receive KRW 12.50000032 billion in funding	Dec. 17	CI
OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002	Nov. 13	CI
OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding	23-09-17	CI
OLIPASS Corporation announced that it expects to receive KRW 4.999998885 billion in funding	23-09-03	CI
OLIPASS Corporation announced that it expects to receive KRW 4.99998978 billion in funding	23-09-03	CI
OLIPASS Corporation(KOSDAQ:A244460) dropped from S&P Global BMI Index	23-08-24	CI
OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients	23-03-16	CI
OLIPASS Corporation announced that it expects to receive KRW 2.999989475 billion in funding from BNB Asset Co., Ltd.	22-12-12	CI
Vanda Pharmaceuticals Inc. and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics	22-09-29	CI
OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002	22-07-18	CI
OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002	22-02-18	CI
OLIPASS Corporation Announces SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage	21-10-25	CI
OLIPASS Corporation announced that it has received KRW 35.4996288 billion in funding from a group of investors	20-11-29	CI
OLIPASS Corporation announced that it expects to receive KRW 35.4996288 billion in funding from a group of investors	20-11-17	CI
OLIPASS Corporation(KOSDAQ:A244460) added to S&P Global BMI Index	20-09-21	CI
OLIPASS Corporation announced that it has received KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	19-12-19	CI
OLIPASS Corporation announced that it expects to receive KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	19-12-17	CI
OLIPASS Corporation has completed an IPO in the amount of KRW 14 billion.	19-09-19	CI
OLIPASS Corporation has filed an IPO.	19-04-22	CI
Olipass Co., Ltd. announced that it has received KRW 19.99992 billion in funding from a group of investors	17-11-29	CI
Olipass Co., Ltd. announced that it expects to receive KRW 19.99992 billion in funding from SV Investment Corp., Geon Investment Co., Ltd., Mirae Asset Venture Investment Co., Ltd., KDB Capital Corporation, Investment Arm, Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm	17-11-05	CI
OLIPASS Corporation announced that it has received KRW 2.00002 billion in funding	17-08-09	CI

OliPass Corporation is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OLIPASS CORPORATION	-32.95%	13.24M
VERTEX PHARMACEUTICALS INCORPORATED	+7.11%	111B
REGENERON PHARMACEUTICALS, INC.	+10.14%	106B
BIONTECH SE	-12.31%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-9.29%	16.81B
SAREPTA THERAPEUTICS, INC.	+38.65%	12.54B
LEGEND BIOTECH CORPORATION	-24.90%	8.09B

Bio Therapeutic Drugs